Vibegron persists in 60% of OAB patients after one year according to a new study....
New research links sputum color in bronchiectasis to airway inflammation and drug response, offering a...
The FDA approved bepirovirsen for chronic HBV treatment, marking the first antisense oligonucleotide for this...
Targeted therapies are offering new hope for myasthenia gravis patients by addressing treatment gaps and...
Study suggests warfarin may be a viable option for low-risk atrial fibrillation patients when cost...
U.S. alopecia guidelines name oral JAK inhibitors first-line therapy, recommends FDA-approved drugs for severe cases...
An experimental drug shows promise in protecting heart function for muscular dystrophy patients by reducing...
Bispecific antibodies are emerging immunotherapy for relapsed lymphoma and leukemia, offering a viable option when...
Heart failure management is shifting as pharmacists take on a larger role. Discover how they...
Proton pump inhibitors may reduce the benefit of durvalumab consolidation after chemoradiotherapy for unresectable stage...